Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanogen's Darbepoetin Alfa vs Aranesp in Anemia of CKD
NCT05636891Phase 1Completed
- Sponsor
- Nanogen Pharmaceutical Biotechnology JSC
- Start
- Sep 2021
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of darbepoetin alfa in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Nanogen Pharmaceutical Biotechnology JSC. Primary endpoints: Maximum Observed Serum Concentration at 336 hours and Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 336 hours. Started Sep 2021; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT05636891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636891.